仅供教育参考，不构成投资建议
基因编辑的经济学
这个行业如何融资、资金的实际用途，以及临床成功为何如此难以预测。
上市公司
CRISPR Decoded 收录的已上市基因编辑公司。我们不提供实时市场数据——市值等数据时刻变动，因此我们为您链接至原始数据来源，而非显示一个您读到时可能已经过时的数字。
| 企业 | 股票代码 | 交流 | 总部 | 平台 | 当前阶段 |
|---|---|---|---|---|---|
| CRISPR Therapeutics | CRSP | Nasdaq | Zug, Switzerland | CRISPR-Cas9 platform | Approved |
| Intellia Therapeutics | NTLA | Nasdaq | Cambridge, Massachusetts | In vivo CRISPR platform | Phase III |
| Beam Therapeutics | BEAM | Nasdaq | Cambridge, Massachusetts | Base editing platform | Phase III |
| Editas Medicine | EDIT | Nasdaq | Cambridge, Massachusetts | In vivo editing | Preclinical |
| Prime Medicine | PRME | Nasdaq | Cambridge, Massachusetts | Prime editing platform | Phase I/II |
| Caribou Biosciences | CRBU | Nasdaq | Berkeley, California | Cell therapy | Phase I |
| Sana Biotechnology | SANA | Nasdaq | Seattle, Washington | Cell engineering | Phase I |
| Vertex Pharmaceuticals | VRTX | Nasdaq | Boston, Massachusetts | Large biotechnology | Approved |
| Sangamo Therapeutics | SGMO | Nasdaq | Richmond, California | Zinc finger platform | Phase III |
| Eli Lilly and Company | LLY | NYSE | Indianapolis, Indiana | Large pharmaceutical | Phase II |
私营企业
风险投资支持或私人持有。融资数据来自各公司官方公告，每份档案均注明日期。
Boston, Massachusetts
Verve Therapeutics
Built to turn heart disease into a one-time treatment, and acquired by Eli Lilly in 2025…
已融资: Acquired by Eli Lilly for ~$1 billion plus CVR
Alameda, California
Scribe Therapeutics
Co-founded by Jennifer Doudna to engineer CRISPR enzymes from scratch rather than use the…
Brisbane, California
Mammoth Biosciences
Co-founded by Jennifer Doudna around ultra-compact CRISPR proteins small enough to fit…
Cambridge, Massachusetts
Arbor Biotechnologies
Co-founded by Feng Zhang and David Scott to discover new editing enzymes from nature at…
Somerville, Massachusetts
bluebird bio
A pioneer of lentiviral gene addition with several approved therapies, and a cautionary…
Somerville, Massachusetts
Tessera Therapeutics
Developing 'gene writing': mobile genetic elements repurposed to insert whole sequences…
Durham, North Carolina
Tune Therapeutics
Turning genes up and down without changing sequence: epigenetic editing taken into early…
行业列表
了解经济学背景
为什么一次性疗法在商业上如此困难，优先审评凭证的价值几何，以及基因疗法的定价方式。
企业、融资与交易动态
来自指定出版商；每条标题均链接至原文。
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
A patient has died in a Bristol Myers Squibb study of autoimmune CAR-T, the same technology that was called into question this summer when both Bristol…
Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3B
Germany's Merck KGaA agreed to buy UK drug developer Silence Therapeutics for $1.3 billion, building out its work in rare and specialty diseases using…
ADC Development from Concept to Clinic
This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics. The post ADC Development from Concept to Clinic…
Estuary debuts with $103M to develop kidney disease gene therapies
Estuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most…
Parkinson's cell therapy biotech Aspen and I&I startup Bambusa file for IPOs
A Gilead-backed cell therapy maker and an I&I biotech from BioNTech vets are looking to ride the biotech industry's IPO momentum. Aspen Neuroscience and…
在哪里获取我们未收录的数据
公司文件
对于在美上市公司，SEC EDGAR系统收录了年度报告（10-K）和季度报告（10-Q），包含现金状况和运营支出——这是评估一家尚未盈利的生物科技公司最关键的两项数据。